FALEC; focally amplified long non-coding RNA in epithelial cancer (1)

Gene Summary

Gene:FALEC; focally amplified long non-coding RNA in epithelial cancer
Aliases: FAL1, ncRNA-a1, LINC00568
Databases:OMIM, HGNC, Ensembl, GeneCard, Gene
Updated:18 December, 2014

Cancer Overview

Research Indicators

Publications Per Year (1989-2014)
Graph generated 18 December 2014 using data from PubMed using criteria.

Literature Analysis

Mouse over the terms for more detail; many indicate links which you can click for dedicated pages about the topic.

  • BMI1
  • Ovarian Cancer
  • Long Noncoding RNA
  • CDKN1A
  • Polycomb Repressive Complex 1
  • Genomics
  • Gene Expression
  • Cell Aging
  • Oncogenes
  • CDKN1A
  • Cancer Gene Expression Regulation
  • Protein Stability
  • Transcriptome
  • Glandular and Epithelial Cancers
  • Single Nucleotide Polymorphism
  • Chromosome 1
  • Tumor Burden
  • RNA Interference
Tag cloud generated 18 December, 2014 using data from PubMed, MeSH and CancerIndex

Notable (1)

Scope includes mutations and abnormal protein expression.

Entity Topic PubMed Papers
Ovarian CancerFALEC and Ovarian Cancer View Publications2

Note: list is not exhaustive. Number of papers are based on searches of PubMed (click on topic title for arbitrary criteria used).

Related Links

Latest Publications: FALEC (cancer-related)

Hu X, Feng Y, Zhang D, et al.
A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer.
Cancer Cell. 2014; 26(3):344-57 [PubMed] Article available free on PMC after 08/09/2015 Related Publications
In a genome-wide survey on somatic copy-number alterations (SCNAs) of long noncoding RNA (lncRNA) in 2,394 tumor specimens from 12 cancer types, we found that about 21.8% of lncRNA genes were located in regions with focal SCNAs. By integrating bioinformatics analyses of lncRNA SCNAs and expression with functional screening assays, we identified an oncogene, focally amplified lncRNA on chromosome 1 (FAL1), whose copy number and expression are correlated with outcomes in ovarian cancer. FAL1 associates with the epigenetic repressor BMI1 and regulates its stability in order to modulate the transcription of a number of genes including CDKN1A. The oncogenic activity of FAL1 is partially attributable to its repression of p21. FAL1-specific siRNAs significantly inhibit tumor growth in vivo.

Related: CDKN1A Ovarian Cancer BMI1

Athie A, Huarte M
FAL1ing inside an amplicon.
Cancer Cell. 2014; 26(3):303-4 [PubMed] Related Publications
Frequently amplified regions of the cancer genome contain well-known oncogenes. In this issue of Cancer Cell, Hu and colleagues discover that FAL1, a long noncoding RNA is encoded in one of these regions. FAL1 acts as an oncogene by stabilizing BMI1, which results in the repression of CDKN1A expression.

Related: CDKN1A Ovarian Cancer BMI1


Found this page useful?

Disclaimer: This site is for educational purposes only; it can not be used in diagnosis or treatment.

Cite this page: Cotterill SJ. FALEC, Cancer Genetics Web: http://www.cancerindex.org/geneweb/FALEC.htm Accessed: date

Creative Commons License
This page in Cancer Genetics Web by Simon Cotterill is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Note: content of abstracts copyright of respective publishers - seek permission where appropriate.

 [Home]    Page last revised: 18 December, 2014     Cancer Genetics Web, Established 1999